MRNA Moderna Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: MRNA

Price (delayed)

$130.51

Market cap

$49.75B

P/E Ratio

10.64

Dividend/share

N/A

EPS

$12.27

Enterprise value

$47.24B

Moderna is an American, Cambridge, Massachusetts-based biotechnology company focused on drug discovery, drug development, and vaccine technologies based exclusively on messenger RNA . The Moderna technology platform is to insert ...

Highlights
The quick ratio has soared by 99% YoY and by 25% from the previous quarter
The equity is up by 10% YoY
The debt has grown by 25% year-on-year but it has declined by 8% since the previous quarter
The net income has plunged by 67% YoY and by 43% from the previous quarter
The company's EPS has shrunk by 66% YoY and by 42% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: https://www.modernatx.com/
Peers: RGLS MRK ATHX ARWR

Key stats

What are the main financial stats of MRNA
Market
Shares outstanding
381.21M
Market cap
$49.75B
Enterprise value
$47.24B
Valuations
Price to earnings (P/E)
10.64
Price to book (P/B)
2.67
Price to sales (P/S)
3.35
EV/EBIT
9.37
EV/EBITDA
8.77
EV/Sales
3.14
Earnings
Revenue
$15.06B
EBIT
$5.04B
EBITDA
$5.39B
Free cash flow
$612M
Per share
EPS
$12.27
Free cash flow per share
$1.59
Book value per share
$48.82
Revenue per share
$39.01
TBVPS
$62.5
Balance sheet
Total assets
$24.13B
Total liabilities
$5.26B
Debt
$927M
Equity
$18.86B
Working capital
$8.62B
Liquidity
Debt to equity
0.05
Current ratio
3.46
Quick ratio
2.87
Net debt/EBITDA
-0.47
Margins
EBITDA margin
35.8%
Gross margin
65.5%
Net margin
31.8%
Operating margin
32.1%
Efficiency
Return on assets
18.7%
Return on equity
25.9%
Return on invested capital
28.3%
Return on capital employed
24.4%
Return on sales
33.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

MRNA stock price

How has the Moderna stock price performed over time
Intraday
1.55%
1 week
3.38%
1 month
-0.68%
1 year
-6.9%
YTD
-27.34%
QTD
-15.02%

Financial performance

How have Moderna's revenue and profit performed over time
Revenue
$15.06B
Gross profit
$9.87B
Operating income
$4.83B
Net income
$4.78B
Gross margin
65.5%
Net margin
31.8%
The operating income has plunged by 70% YoY and by 49% from the previous quarter
The net income has plunged by 67% YoY and by 43% from the previous quarter
Moderna's operating margin has shrunk by 55% YoY and by 34% QoQ
The net margin has dropped by 51% year-on-year and by 27% since the previous quarter

Growth

What is Moderna's growth rate over time

Valuation

What is Moderna stock price valuation
MRNA P/E details
P/E
10.64
P/B
2.67
P/S
3.35
EV/EBIT
9.37
EV/EBITDA
8.77
EV/Sales
3.14
The company's EPS has shrunk by 66% YoY and by 42% QoQ
The stock's P/E is 46% above its last 4 quarters average of 7.3
MRNA's P/B is 63% below its 5-year quarterly average of 7.2 and 14% below its last 4 quarters average of 3.1
The equity is up by 10% YoY
The stock's P/S is 94% below its 5-year quarterly average of 52.6 but 8% above its last 4 quarters average of 3.1
MRNA's revenue is down by 33% year-on-year and by 22% since the previous quarter

Efficiency

How efficient is Moderna business performance
The ROIC has plunged by 86% YoY and by 50% from the previous quarter
MRNA's return on equity has dropped by 79% year-on-year and by 44% since the previous quarter
Moderna's ROA has plunged by 71% YoY and by 41% from the previous quarter
The company's return on sales has shrunk by 53% YoY and by 33% QoQ

Dividends

What is MRNA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for MRNA.

Financial health

How did Moderna financials performed over time
The quick ratio has soared by 99% YoY and by 25% from the previous quarter
The current ratio has surged by 95% year-on-year and by 27% since the previous quarter
The debt is 95% smaller than the equity
The company's debt to equity rose by 25% YoY
The debt has grown by 25% year-on-year but it has declined by 8% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.